Dipeptidyl peptidase‐IV inhibitors are emerging kind of oral hypoglycemic agent which reduce the proliferation of cancer cells by inactivating YAP in a LATS homolog-dependent way, and this inhibition can be blocked by AMPK (62). The gene discussed is YAP1; the disease is cancer.